Biocon sees larger licensing income from pharma

Biocon, India's top-listed biotechnology company, expects to generate larger licensing income from pharmaceuticals business, its Chairman and Managing Director said on Wednesday.

The Bangalore-based drugmaker earlier said consolidated net profit fell 15.8% in December quarter, while revenue rose 3%.
The sales growth in the fiscal third quarter ended December 31 was flat on lower licensing income, Kiran Mazumdar-Shaw, told a television channel.
The company said, licensing fees and income dropped to Rs 29.2 crore in October-December from Rs 76.8 crore a year earlier.